[
  {
    "ts": null,
    "headline": "Unlocking Pfizer's Value: Cost Controls And Oncology Pipeline",
    "summary": "Pfizer remains a strong Buy with robust cost controls, EPS growth, and a promising pipeline, despite challenges. See more on PFE stock here.",
    "url": "https://finnhub.io/api/news?id=361527c8b7da99af29880e07b798b99f99e3ebd5b623934cffe6ac93788e89d2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748383938,
      "headline": "Unlocking Pfizer's Value: Cost Controls And Oncology Pipeline",
      "id": 134736809,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418907713/image_1418907713.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer remains a strong Buy with robust cost controls, EPS growth, and a promising pipeline, despite challenges. See more on PFE stock here.",
      "url": "https://finnhub.io/api/news?id=361527c8b7da99af29880e07b798b99f99e3ebd5b623934cffe6ac93788e89d2"
    }
  },
  {
    "ts": null,
    "headline": "Merck Proves Why It's Still A Top Pharma Pick",
    "summary": "Merck beats Q1 2025 estimates despite Gardasil sales drop, driven by Vaxneuvance, Winrevair & Welireg.",
    "url": "https://finnhub.io/api/news?id=0cd74fb2506cf79a35bbc4e590465ab9d359d893b4ba9d191509d006f7ab888a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748360766,
      "headline": "Merck Proves Why It's Still A Top Pharma Pick",
      "id": 134714927,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1357662733/image_1357662733.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Merck beats Q1 2025 estimates despite Gardasil sales drop, driven by Vaxneuvance, Winrevair & Welireg.",
      "url": "https://finnhub.io/api/news?id=0cd74fb2506cf79a35bbc4e590465ab9d359d893b4ba9d191509d006f7ab888a"
    }
  },
  {
    "ts": null,
    "headline": "US drops COVID vaccine recommendation for healthy kids, pregnant women",
    "summary": "The U.S. has stopped recommendingroutine COVID-19 vaccinations for pregnant women and healthychildren, Health Secretary Robert F. Kennedy Jr. announced in asocial media post on Tuesday,...",
    "url": "https://finnhub.io/api/news?id=245fcd35d2aa98125c25c0e09d5dff6e37fe25fe7893c905f24cb6c9fd46a18a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748354464,
      "headline": "US drops COVID vaccine recommendation for healthy kids, pregnant women",
      "id": 134710184,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "The U.S. has stopped recommendingroutine COVID-19 vaccinations for pregnant women and healthychildren, Health Secretary Robert F. Kennedy Jr. announced in asocial media post on Tuesday,...",
      "url": "https://finnhub.io/api/news?id=245fcd35d2aa98125c25c0e09d5dff6e37fe25fe7893c905f24cb6c9fd46a18a"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer Stock a Buy After This $1.25 Billion Investment?",
    "summary": "Pfizer is licensing a promising investigational cancer medicine from a smaller company.  This move improves the drugmaker's already attractive oncology pipeline.  Pfizer should eventually bounce back, thanks to its deep pipeline and improving efficiency.",
    "url": "https://finnhub.io/api/news?id=5c35b1c416692562faae1a07792bab237e33b423688b0960c5a9f48a48e329a5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748354400,
      "headline": "Is Pfizer Stock a Buy After This $1.25 Billion Investment?",
      "id": 134716325,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer is licensing a promising investigational cancer medicine from a smaller company.  This move improves the drugmaker's already attractive oncology pipeline.  Pfizer should eventually bounce back, thanks to its deep pipeline and improving efficiency.",
      "url": "https://finnhub.io/api/news?id=5c35b1c416692562faae1a07792bab237e33b423688b0960c5a9f48a48e329a5"
    }
  },
  {
    "ts": null,
    "headline": "Kennedy, Skipping Regulatory Steps, Limits Use of Covid-19 Shots",
    "summary": "Kennedy, Skipping Regulatory Steps, Limits Use of Covid-19 Shots",
    "url": "https://finnhub.io/api/news?id=cb5f9c2a3b14adbe96627fb2e0f265561a66a2f4991b37c9c98f0dbb9920e651",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748354340,
      "headline": "Kennedy, Skipping Regulatory Steps, Limits Use of Covid-19 Shots",
      "id": 134713777,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Kennedy, Skipping Regulatory Steps, Limits Use of Covid-19 Shots",
      "url": "https://finnhub.io/api/news?id=cb5f9c2a3b14adbe96627fb2e0f265561a66a2f4991b37c9c98f0dbb9920e651"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=5c3d80902435564787a02bbd7f97fb5c324b8afbcb22cc7d465e603dfcb225a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748350812,
      "headline": "Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 134716326,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=5c3d80902435564787a02bbd7f97fb5c324b8afbcb22cc7d465e603dfcb225a4"
    }
  },
  {
    "ts": null,
    "headline": "Gene Therapy Death Worsens Picture for an Already Troubled Field",
    "summary": "Gene Therapy Death Worsens Picture for an Already Troubled Field",
    "url": "https://finnhub.io/api/news?id=e19f1a8d0889607602e4f06896446388c21b054b4eb93fd588d6ff9472ad0e16",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748347860,
      "headline": "Gene Therapy Death Worsens Picture for an Already Troubled Field",
      "id": 134713778,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Gene Therapy Death Worsens Picture for an Already Troubled Field",
      "url": "https://finnhub.io/api/news?id=e19f1a8d0889607602e4f06896446388c21b054b4eb93fd588d6ff9472ad0e16"
    }
  },
  {
    "ts": null,
    "headline": "US drops COVID vaccine recommendations for healthy children, pregnant women",
    "summary": "The Centers for Disease Control andPrevention has stopped recommending routine COVID-19vaccinations for pregnant women and healthy children, U.S.health regulators said on Tuesday. ...",
    "url": "https://finnhub.io/api/news?id=fdafd49a8a6510faea4786b9d94bbfe239976fbef82220e54d433d18258e74de",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748342530,
      "headline": "US drops COVID vaccine recommendations for healthy children, pregnant women",
      "id": 134708985,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "The Centers for Disease Control andPrevention has stopped recommending routine COVID-19vaccinations for pregnant women and healthy children, U.S.health regulators said on Tuesday. ...",
      "url": "https://finnhub.io/api/news?id=fdafd49a8a6510faea4786b9d94bbfe239976fbef82220e54d433d18258e74de"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer headquarters conversion project in Manhattan gets $720m loan",
    "summary": "The project will feature more than 100,000ft² of amenities and approximately 30,000ft² of ground-floor retail space.",
    "url": "https://finnhub.io/api/news?id=af7f1528546b1f7baf7bbe7b33632128dd85b55f1ab79d2a2567362755522c48",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748337671,
      "headline": "Pfizer headquarters conversion project in Manhattan gets $720m loan",
      "id": 134716328,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The project will feature more than 100,000ft² of amenities and approximately 30,000ft² of ground-floor retail space.",
      "url": "https://finnhub.io/api/news?id=af7f1528546b1f7baf7bbe7b33632128dd85b55f1ab79d2a2567362755522c48"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb At ASCO 2025: A Resilient Play Amid Market Turbulence",
    "summary": "Bristol-Myers Squibb's financial position improved, it raised both its EPS guidance and revenue expectations, and Opdivo's received approval. Read why BMY earns a Strong Buy upgrade.",
    "url": "https://finnhub.io/api/news?id=a41431c2d4892c93c6a1f427c58b54bbb57173440bfde20a0424a9348bd7a705",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748337274,
      "headline": "Bristol-Myers Squibb At ASCO 2025: A Resilient Play Amid Market Turbulence",
      "id": 134708601,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/640215102/image_640215102.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibb's financial position improved, it raised both its EPS guidance and revenue expectations, and Opdivo's received approval. Read why BMY earns a Strong Buy upgrade.",
      "url": "https://finnhub.io/api/news?id=a41431c2d4892c93c6a1f427c58b54bbb57173440bfde20a0424a9348bd7a705"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics: Buy It For The Future And Ignore The Noise",
    "summary": "Viking Therapeutics: Buy It For The Future And Ignore The Noise",
    "url": "https://finnhub.io/api/news?id=775c3709e392fdfa3d0b9321e9163a4d42e71a62639d4c48f0819fdfab765624",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748336400,
      "headline": "Viking Therapeutics: Buy It For The Future And Ignore The Noise",
      "id": 134708461,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=775c3709e392fdfa3d0b9321e9163a4d42e71a62639d4c48f0819fdfab765624"
    }
  }
]